

Revised Draft Agenda
Biocides Working Group Meeting IV-2020
17-26 November 2020

WG-IV-2020 meetings are held as virtual meetings via WebEx

The time is indicated in Helsinki time.

Tue 17 November	10:00-17:00	APCP WG WebEx
Wed 18 November	10:00-17:00	ENV WG WebEx
Thu 19 November	10:00-16:00	ENV WG WebEx
Tue 24 November	10:00-17:00	TOX WG WebEx
Wed 25 November	10:00-17:00	TOX WG WebEx
Tue 24 November	10:30-17:30	EFF WG WebEx
Thu 26 November	10:00-17:00	EFF WG WebEx

Analytical methods and physico-chemical properties Working Group		
Chair: Bernhard Krebs		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda <i>For agreement</i>		
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes of WG III 2020 <ul style="list-style-type: none"> • <i>WG III 2020_APCP_7-1</i> • <i>WG III 2020_APCP_8-1</i> • <i>WG III 2020_APCP_8-2</i> • <i>WG III 2020_APCP_Gen agenda items</i> <i>For agreement</i>		
Item 6 - Discussion of Union Authorisations		eCA
6.1	UA for product family containing Peracetic acid PT 02, 03, 04, 05 (BC-KV033704-17) Meeting document: <i>WG IV 2020_APCP_6-1</i> <i>For agreement</i>	BE
Item 7 – AOB		

Environment Working Group Chair: Heike Schimmelpfennig		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes of WG-III-2020 <ul style="list-style-type: none"> • <i>WG-III-2020_ENV_6-1</i> • <i>WG-III-2020_ENV_6-2</i> • <i>WG-III-2020_ENV_6-3</i> • <i>WG-III-2020_ENV_7-1</i> • <i>WG-III-2020_ENV_General_minutes</i> 		<i>For agreement</i>
Item 6 - Discussion of Active Substances (Day 1)		eCA
6.1	Sulphur dioxide generated from sulphur by combustion – ED Assessment PT 4 Meeting documents: <i>WGIV2020_ENV_6-1</i>	DE <i>For agreement</i>
6.2	Sulfur dioxide released from sodium metabisulfite – ED Assessment PT 9 Meeting documents: <i>WGIV2020_ENV_6-2</i>	DE <i>For agreement</i>
6.3	Medetomidine e-consultation on PT 21 data requirements (renewal) PT 21 Meeting documents: <i>WGIV2020_ENV_6-3</i>	NO <i>For agreement</i>
6.4	Early WG: PNEC aquatic for benzyl alcohol PT 6 Meeting documents: <i>WGIV2020_ENV_6-4</i>	NL <i>For agreement</i>

Item 7 - Discussion of Union Authorisations (Day 2)		eCA
7.1	<p>UA for product family containing peracetic acid PT 02, 03, 04, 05 (BC-KV033704-17) Meeting document: <i>WGIV2020_ENV_7-1</i></p> <p style="text-align: right;"><i>For agreement</i></p>	BE
7.2	<p>Early WG: UA for a product containing cyromazine Follow up e-consultation (BC-TH035808-24) Meeting document: <i>WGIV2020_ENV_7-2</i></p> <p style="text-align: right;"><i>For agreement</i></p>	CH
7.3	<p>General discussion: worst case values for exposure scenarios Meeting document: <i>WGIV2020_ENV_7-3</i></p> <p style="text-align: right;"><i>For agreement</i></p>	SECR
Item 8 – Technical and guidance related issues (Day 1 or 2)		Presenter
8.1	<p>Overview on guidance Meeting document: <i>WGIV2020_ENV_8-1</i></p> <p style="text-align: right;"><i>For information</i></p>	SECR
8.2	<p>Conclusions of AHEE-5 follow ups Meeting document: <i>WGIV2020_ENV_8-2</i></p> <p style="text-align: right;"><i>For agreement</i></p>	SECR
8.3	<p>Use of the XETA assay in the ED assessment SECR to inform</p> <p style="text-align: right;"><i>For information</i></p>	SECR
Item 9 – AOB (Day 1)		
9.1	<p>Other information & lessons learned SECR to inform</p> <p style="text-align: right;"><i>For information</i></p>	SECR

Human Health Working Group		
Chair: Antero Airaksinen		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-III-2020		
<ul style="list-style-type: none"> • <i>WG-III-2020_TOX_6-1</i> • <i>WG-III-2020_TOX_6-2</i> • <i>WG-III-2020_TOX_6-3</i> • <i>WG-III-2020_TOX_7-1</i> • <i>WG-III-2020_TOX_7-2</i> • <i>WG-III-2020_TOX_Minutes</i> 		<i>For agreement</i>
Item 6 - Discussion of Active Substances		eCA
6.1	Sulphur dioxide generated from sulphur by combustion – ED Assessment and closing ad hoc follow-up from WG-II-2019 PT 4 Meeting documents: <i>WGIV2020_TOX_6-1</i>	DE
		<i>For agreement</i>
6.2	Sulfur dioxide released from sodium metabisulfite – ED Assessment and closing ad hoc follow-up from WG-II-2019 PT 9 Meeting documents: <i>WGIV2020_TOX_6-2</i>	DE
		<i>For agreement</i>
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product family containing Peracetic acid PT 02, 03, 04, 05 (BC-KV033704-17) Meeting document: <i>WGIV2020_TOX_7-1</i>	BE
		<i>For agreement</i>
Item 8 - Technical and guidance related issues		Presenter
8.1	Update on guidance development Meeting document: <i>WGIV2020_TOX_8-1</i>	SECR
		<i>For discussion</i>

8.2	Dermal absorption of rodenticides Meeting document: <i>WGIV2020_TOX_8-2</i> <i>For agreement</i>	DE
Item 9 – AOB		Presenter
9.1	Other information & lessons learned Meeting document: <i>WGIV2020_TOX_9-1</i> <i>For discussion</i>	SECR
9.2	Training session: in vitro methods and ToxCast in assessing endocrine disruption 2 h session planned <i>For information</i>	SECR

Efficacy Working Group		
Chair: Katarzyna Szymankiewicz		
Item 1 - Welcome and apologies		
Item 2 – Administrative issues		
Item 3 – Agreement of the agenda		<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda		
Item 5 – Agreement of the draft minutes from WG-III-2020		
<ul style="list-style-type: none"> • <i>WG-III-2020_EFF_6-1</i> • <i>WG-III-2020_EFF_6-2</i> • <i>WG-III-2020_EFF_6-3</i> • <i>WG-III-2020_EFF_7-1</i> • <i>WG-III-2020_EFF_7-2</i> • <i>WG-III-2020_EFF_Minutes</i> 		<i>For agreement</i>
Item 6 – Discussion of Active Substances		eCA
6.1	Early WG discussion on Chrysanthemum cinerariaefolium PT18 Meeting document: <i>WGIV2020_EFF_6-1</i>	ES <i>For agreement</i>
Item 7 - Discussion of Union Authorisations		eCA
7.1	UA for product family containing Peracetic acid PT 02, 03, 04, 05 (BC-KV033704-17) Meeting document: <i>WGIV2020_EFF_7-1</i>	BE <i>For agreement</i>
Item 8 - Technical and guidance related issues		
8.1	Vol. II, Parts B+C – Appendix 4 Meeting document: <i>WGIV2020_EFF_8-1</i>	ECHA <i>For discussion</i>
8.2	TAB proposals: <ul style="list-style-type: none"> • PT18 crack and crevice treatment test Meeting document: <i>WGIV2020_EFF_8-2a</i> • Attractants in PT18 bait products Meeting document: <i>WGIV2020_EFF_8-2b</i> 	NL/DE <i>For discussion</i>

8.3	Certification of testing laboratories for disinfectant efficacy testing Meeting document: <i>WGIV2020_EFF_8-3</i> <i>For discussion</i>	DE
Item 9 – AOB		
9.1	Other information & lessons learned Meeting document: <i>WGIV2020_EFF_9-1</i> <i>For information</i>	ECHA
9.2	Preventive treatment of wood against the installation of wasp nests – outcome of the e-consultation (closed session) Meeting document: <i>WGIV2020_EFF_9-2</i> <i>For discussion</i>	BE